Inclusion of metastatic patients and use of less robust statistical methods in previous studies may have contributed to this difference of results.[25] However, after exclusion of metastatic patients and adapting HRs and their corresponding 95% CIs as outcome estimates, the association of HER-2 overexpression and reduced survival was still stable for Onda et al's[7] and Gorlick et al's[27] studies, and for the pooled outcome estimate of OS of localized osteosarcoma in our meta-analysis. The gene discussed is ERBB2; the disease is osteosarcoma.